Uterine myoma: new and perspective options for medicinal treatment
https://doi.org/10.21518/2079-701X-2020-3-49-58
Abstract
The review provides information on the medical treatment of uterine fibroids (MM) in a comparative aspect. MM are one of the most common gynecological diseases requiring surgical intervention in the presence of symptoms. As a drug treatment, gestagens and their combinations with estrogens, which did not demonstrate reliable efficacy, were the first to be proposed. Later, obvious advantages of using GnRH agonists/antagonists that cause the effect of “central” chemical castration were discovered, and therefore their use is limited to 6 months, and they are successfully used to prepare patients for surgery. Recently, non-peptide orally active GnRH receptor antagonists have been proposed that are in the early stages of clinical trials. However, changes in the dosage form and route of administration of drugs that inhibit the activity of GRH do not improve their safety profile. Another breakthrough in MM therapy has been the use of selective progesterone receptor modulators, previously called “antiprogestins.” The drugs of this group have comparable efficacy and better tolerance to AGnRH, which makes the possible long-term treatment of uterine fibroids, especially in premenopausal women, using these drugs.
About the Authors
E. N. Kareva
Moscow State Medical University named after I.M. Sechenov (Sechenov University);
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Elena N. Kareva, Dr. of Sci. (Med.), Professor, Chair for Pharmacology, Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University); Professor, Chair for Molecular Pharmacology and Radiobiology named after Academician P.V. Sergeev, Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University“ of the Ministry of Health of the Russian Federation
8, p. 2, Trubetskaya St., Moscow, 119991,
1, Ostrovityanova St., Moscow, 117997
Т. Е. Samoylova
National Medical and Surgical Center named after N.I. Pirogov
Russian Federation
Russian Federation
Tatiana E. Samoylova, Dr. of Sci. (Med.), Professor, Chair for Gynecopathy and Reproductive Health, Institute for Advanced Physicians
65, Nizhnyaya Pervomayskaya St., Moscow, 105203
References
1. Farris M., Bastianelli C., Rosato E., Benagiano B.I.G. Uterine fibroids: an update on current and emerging medical treatment options. Therapeutics and Clinical Risk Management. 2019;15:157–178. doi: 10.2147/TCRM.S147318.
2. Gurusamy K.S., Vaughan J., Fraser I.S., Best L.M.J., Richards T. Medical therapies for uterine fibroids – a systematic review and network meta-analysis of randomised controlled trials. PLoS One. 2016;11(2):e0149631. doi: 10.1371/journal.pone.0149631.
3. Bartels C.B., Cayton K.C., Chuong F.S., et al. Anevidence-basedapproach to the medical management of fibroids: a systematic review. Clin Obstet Gynecol. 2016;59(1):30–52. doi: 10.1097/GRF.0000000000000171.
4. Nakai G., Yamada T., Hamada T. et al. Pathological findings of uterine tumors preoperatively diagnosed as red degeneration of leiomyoma by MRI. Abdom Radiol. 2017;42(7):1825–1831. doi: 10.1007/s00261-017-1126-3.
5. Xu Q., Ohara N., Liu J. et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14(3):181–191. doi: 10.1093/molehr/gan004.
6. Ross R.K., Pike M.C., Vessey M.P. et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J. 1986;293(6543):359–362. doi: 10.1136/bmj.293.6543.359
7. Parazzini F., La Vecchia C., Negri E. et al. Epidemiological characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol. 1988;72(6):853–857. doi: 10.1097/00006250-198812000-00008.
8. Samadi A.R., Lee N.C., Flanders W.D. et al. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health. 1996;86(6):858– 862. doi: 10.2105/ajph.86.6.858.
9. Friedman A.J., Thomas P.P. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol. 1995;85(4):631–635. doi: 10.1016/0029-7844(95)00007-E.
10. Ortmann O., Weiss J.M., Diedrich K. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online. 2002;5(Suppl 1):1–7. doi: 10.1016/s1472-6483(11)60210-1.
11. Candiani G.B., Vercellini P., Fedele L. et al. Use of goserelin depot, a gonadotropin releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet Gynecol Scand. 1990;69(5):413–415. doi: 10.3109/00016349009013304.
12. Matta W.H.M., Stabile I., Shaw R.W., Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin releasing hormone agonist buserelin. Fertil Steril. 1988;49(6):1083–1085. doi: 10.1016/s0015-0282(16)59966-x.
13. Benagiano G., Morini A., Primiero F.M. Fibroids: overview of current and future treatment options. Br J Obstet Gynaecol. 1992;99(s7):18–22. doi: 10.1111/j.1471-0528.1992.tb13534.x.
14. Dodirot V., Dubuisson J.-B., Chapron C. et al. Recurrence of leiomyomata after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc. 2001;8(4):495–500. doi: 10.1016/s1074-3804(05)60610-x.
15. Fedele L., Vercellini P., Bianchi S. et al. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br J Obstet Gynaecol. 1990;97(5):393–396. doi: 10.1111/j.1471-0528.1990.tb01824.x.
16. Friedman A.J., Daly M., Juneau-Norcross M. et al. Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil Steril. 1992;58(1):205–208. doi: 10.1016/s00150282(16)55164-4.
17. Broekmans F.J., Hompes P.G.A., Heitbrink M.A. et al. Two-step gonadotropinreleasing hormone agonist treatment of uterine leiomyomas: standarddose therapy followed by reduced-dose therapy. Am J Obstet Gynecol. 1996;175(5):1208–1216. doi: 10.1016/s0002-9378(96)70030-3.
18. Carr B.R., Marshburn P.B., Weatherall P.T. et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 1993;76(5):1217–1223. doi: 10.1210/jcem.76.5.8496313.
19. Palomba S., Orio F. Jr., Russo T. et al. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod. 2004;19(6):1308–1314. doi: 10.1093/humrep/deh296.
20. Moroni R.M., Martins W.P., Ferriani R.A. et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015;(20):CD010854. doi: 10.1002/14651858.CD010854.pub2.
21. Betz S.F., Zhu Y.-F., Chen C., Struthers R.S. Non-peptide gonadotropinreleasing hormone receptor antagonists. J Med Chem. 2008;51(12): 3331– 3348. doi: 10.1021/jm701249f.
22. Zhu Y.-F., Gross T.D., Guo Z. et al. Identification of 1-arylmethyl-3-(2aminoethyl)-5-aryluracil as novel gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2003;46(11):2023–2026. doi: 10.1021/jm034041s.
23. Chen C., Wu D., Guo Z. et al. Discovery of sodium R-(+ )-4-{2-[5-(2-fluoro3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl -2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino} butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008;51(23):7478–7485. doi: 10.1021/jm8006454.
24. Struthers R.S., Xie Q., Sullivan S.K. et al. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropinreleasing hormone receptor, NBI-42902. Endocrinology. 2007;148(2):857–867. doi: 10.1210/en.2006-1213.
25. Carr B., Dmowski W.P., O’Brien C. et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxy-progesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–1351. doi: 10.1177/1933719114549848.
26. Taylor H.S., Giudice L.C., Lessey B.A. et al. Treatment of endometriosisassociated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. doi: 10.1056/NEJMoa1700089.
27. Surrey E., Taylor H.S., Giudice L. et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147–160. doi: 10.1097/AOG.0000000000002675.
28. Archer D.F., Stewart E.A., Jain R.I., et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017;108(1):152–160. doi: 10.1016/j.fertnstert.2017.05.006
29. Kim S.M., Yoo T., Lee S.Y. et al. Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis. Life Sci. 2015;139:166–174. doi: 10.1016/j.lfs.2015.08.016.
30. Kim S.M., Lee M., Lee S.Y. et al. Discovery of an orally bioavailable gonadotropinreleasing hormone receptor antagonist. J Med Chem. 2016;59(19):9150–9172. doi: 10.1021/acs.jmedchem.6b01071.
31. Miwa K., Hitaka T., Imada T., et al. Discovery of 1-{4-[1-(2,6difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin3-yl)2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl] phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2011;54(14):4998–5012. doi: 10.1021/jm200216q.
32. Nakata D., Masaki T., Tanaka A. et al. Suppression of the hypothalamicpituitarygonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167–174. doi: 10.1016/j.ejphar.2013.12.001.
33. Kim J.J., Kurita T., and Bulun S.E. Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer. Endocrine Reviews. 2013;34(1):130–162. doi: 10.1210/er.2012-1043.
34. Cermik D., Arici A., Taylor H.S. Coordinated regulation of HOX gene expression in myometrium and uterine leiomyoma. Fertil Steril. 2002;78(5):979– 984. doi: 10.1016/s0015-0282(02)03366-6.
35. Lamminen S., Rantala I., Helin H. et al. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest. 1992;34(2):111–114. doi: 10.1159/000292738.
36. Palomba S., Sena T., Morelli M. et al. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2002;102(2):199–201. doi: 10.1016/s0301-2115(01)00588-7.
37. Friedman A.J., Daly M., Juneau-Norcross M. et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin “add-back” regimens for women with leiomyomata uteri. J Clin Endocrinol Metab., 1993;76(6):1439–1445. doi: 10.1210/jcem.76.6.8501148.
38. Fiscella K., Eisinger S.H., Meldrum S. et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1381–1387 doi: 10.1097/01.AOG.0000243776.23391.7b.
39. Maruo T., Matsuo H., Shimomura Y. et al. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids. 2003;68(10–13):817–824. doi: 10.1016/j.steroids.2003.08.017.
40. Smith S.K. The regulation of fibroid growth: time for a re-think? Br J Obstet Gynaecol. 1993;100(11):977–978. doi: 10.1111/j.1471-0528.1993.tb15136.x.
41. Spirtas R., Blithe D., Blye R. et al. Contraception & Reproductive Health Branch. NICHD: Report to the NACHHD Council; 2004. Available at: https://www.nichd.nih.gov/publications/pubs/council_crhb_2004/index.
42. Murji A., Whitaker L., Chow T.L., Sobel M.L. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev. 2017;(4):CD010770. doi: 10.1002/14651858.CD010770.pub2.
43. Doherty L., Mutlu L., Sinclair D., Taylor H. Uterine Fibroids: Clinical Manifestations and Contemporary Management, Reprod Sci. 2014;21(9):1067–1092. doi: 10.1177/1933719114533728.
44. Herrmann W., Wyss R., Riondel A., Philibert D., Teutsch G., Sakiz E., Baulieu E.E. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C R Seances Acad Sci III. 1982;294(18):933–938. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6814714.
45. Kareva E.N., Serebrova S.YU., Kochina N.A. et al. Selective Modulators of Progesterone Receptors (Literature Review). Eksperimentalnaya i Klinicheskaya Farmakologiya = Experimental and Clinical Pharmacology. 2018;81(10):36–44. (In Russ.) doi: 10.30906/0869-2092-2018-81-10-36-44.
46. Eisinger S.H., Fiscella J., Bonfiglio T., Meldrum S., Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol. 2009;146(2):215–218. doi: 10.1016/j.ejogrb.2009.06.004.
47. Ray R.K., Samal S. Efficacy of mifepristone in reducing the size of fibroids. J Evid Based Med Healthc. 2018;5(50):3436–3439. doi: 10.18410/jebmh/2018/699.
48. Buyanova S.N., Titchenko L.I., Kareva E.N., Gasparyan N.D, Titchenko L.P., Chechneva M.A. The clinical value of estimation of intratumor blood flow values in the diagnosis of estrogenand progesterone-dependent uterine myoma. Rossiyskiy vestnik akushera-ginekologa = Russian Bulletin of ObstetricianGynecologist. 2006;6(3):42–45. (In Russ.) Available at: https://elibrary.ru/item.asp?id=9247532.
49. Bagaria M., Suneja A., Vaid N.B., Guleria K., Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomized doubleblind placebocontrolled clinical trial. Aust N Z J Obstet Gynaecol. 2009;49(1):77–83. doi: 10.1111/j.1479-828X.2008.00931.x.
50. Seth S., Goel N., Singh E., Mathur A.S., Gupta G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J Midlife Health. 2013;4(1):22–26. doi: 10.4103/0976-7800.109630.
51. Kulshrestha V., Kriplani A., Agarwal N., Sareen N., Garg P., Hari S., Thulkar J. Low dose mifepristone in medical management of uterine leiomyoma – an experience from a tertiary care hospital from north India. Indian J Med Res. 2013;137(6):1154–1162. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23852296.
52. Feng C., Meldrum S., Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. Int J Gynaecol Obstet. 2010;109(2):121–124. doi: 10.1016/j.ijgo.2009.11.019.
53. Kapur A., Angomchanu R., Dey M. Efficacy of use of long-term, low-dose mifepristone for the treatment of fibroids. J Obstet Gynecol India. 2016;66(Suppl 1):494–498. doi: 10.1007/s13224-016-0861-7.
54. Arora D., Chawla J., Kochar S.P.S., Sharma J.C. A randomized control trial to assess efficacy of mifepristone in medical management of uterine fibroid. Med J Armed Forces India. 2017;73(3):267–273. doi: 10.1016/j.mjafi.2017.02.013.
55. Sergeev P.V., Kareva E.N., Gasparyan N.D. et al. Effect of Mifegin on the Content of Cyclic Nucleotides in the Cervical Myometrium in Full-Term Pregnancy. Byulleten’ ehksperimental’noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2002;134(4):349–350. (In Russ.) doi: 10.1023/a:1021900129419.
56. Kareva E.N. Mifepristone and uterine myoma. Farmateka. 2010;(14):18-30. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/7920.
57. Yu S., Yan C., Wu W. et al. RU486 Metabolite Inhibits CCN1/Cyr61 Secretion by MDA-MB-231-Endothelial Adhesion. Front Pharmacol. 2019;10:1296. doi: 10.3389/fphar.2019.01296.
58. Kareva E.N., Gankovskaya L.V., Shimanovsky N.L. Sex steroids and immunity. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology (RJI). 2012;6(1):3–13. (In Russ.) Available at: https://elibrary.ru/item.asp?id=18918115.
59. Engman M., Varghese S., Lagerstedt R.K. et al. GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PLoS One. 2013;8(12):e80114. doi: 10.1371/journal.pone.0080114.
60. Kareva E.N., Bekhbudova L.Kh., Gorenkova O.S., Samoilova T.E. Personalized approach to using mifepristone in patients with uterine myoma. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2015;(5):61–65. (In Russ.) Available at: https://en.aig-journal.ru/articles/Personalizirovannyi-podhod-k-naznacheniu-mifepristona-pacientkam-smiomoimatki.html.
61. Chwalisz K., Perez M.C., Demanno D., Winkel C., Schubert G., Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26(3):423– 438. doi: 10.1210/er.2005-0001.
62. Chwalisz K., Garg R., Brenner R., Slayden O., Winkel C., Elger W. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol. 2006;4(Suppl 1):S8. doi: 10.1186/1477-7827-4-S1-S8.
63. Luo X., Yin P., Coon V.J.S., Cheng Y.H., Wiehle R.D., Bulun S.E. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril. 2010;93(8):2668–2673. doi: 10.1016/j.fertnstert.2009.11.031.
64. Rao P.N., Acosta C.K., Bahr M.L. et al. A practical large-scale synthesis of 17alpha-acetoxy-11beta-(4-N, N-dimethylaminophenyl)-19-norpregna4,9-diene-3,20-dione (CDB-2914). Steroids. 2000;65(7):395–400. doi: 10.1016/s0039-128x(00)00100-8.
65. Xu Q., Takekida S., Ohara N. et al. Progesterone receptor modulator CDB2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5’-diphosphateribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005;90(2):953–961. doi: 10.1210/jc.2004-1569.
66. Xu Q., Ohara N., Chen W. et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod. 2006;21(9):2408–2416. doi: 10.1093/humrep/del159.
67. Kalampokas T., Kamath M., Boutas I., Kalampokas E. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis. Gynecol Endocrinol. 2016;32(2):91–96. doi: 10.3109/09513590.2015.1106471.
68. Pourcelot A.G., Capmas P., Fernandez H. Place of ulipristal acetate in the management of uterine fibroids: preoperative treatment or sequential treatment? J Gynecol Obstet Hum Reprod. 2017;46(3):249–254. doi: 10.1016/j.jogoh.2017.02.001.
69. Williams A.R., Critchley H.O., Osei J., Ingamells S., Cameron I.T., Han C., Chwalisz K. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007;22(6):1696–1704. doi: 10.1093/humrep/dem026.
70. Mutter G.L., Bergeron C., Deligdisch L. et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21(5):591–598. doi: 10.1038/modpathol.2008.19.
71. de Milliano I., van Hattum D., Ket J.C.F. ,Huirne J.A.F., Hehenkamp W.J.K. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2017;214:56–64. doi: 10.1016/j.ejogrb.2017.04.042.
72. Moravek M.B., Yin P., Ono M. et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015;21(1):1-12. doi: /10.1093/humupd/dmu048.
73. Kareva E.N., Bekhbudova L.Kh., Gorenkova O.S., Samoilova T.E. Search for prognostic markers of the undesirable effects of mifepristone in the treatment of uterine myoma. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2016;(4):94-100. (In Russ.) doi: 10.18565/aig.2016.4.94-100.
74. Engman M., Granberg S., Williams A.R. et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870–1879. doi: 10.1093/humrep/dep100.
Review
For citations:
Kareva EN, Samoylova ТЕ. Uterine myoma: new and perspective options for medicinal treatment. Meditsinskiy sovet = Medical Council. 2020;(3):49-58. (In Russ.) https://doi.org/10.21518/2079-701X-2020-3-49-58
Views:
1778
Email this article 